PAR-25-083: Co-infection and Cancer (R21 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on January 7, 2026.
From the official notice on Grants.gov, last changed November 21, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$430,738
- Typical project length2 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under PAR-25-083 were run by National Cancer Institute (NCI, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-25-083 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-23-056 | December 14, 2022 | Closed November 16, 2024 | Closed |
Key dates
| Posted | November 21, 2024 |
|---|---|
| Deadline | January 7, 2026 |
| Archived by Grants.gov | February 12, 2026 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Most of the program's money (64% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.
Funded under PAR-25-083 so far
NIH funded 2 projects under PAR-25-083 in fiscal 2026, at 2 institutions. The median yearly award was $430,738.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Myeloid Phagocyte Activation by Commensal-Activated Complement C5aR1 Signaling: Implications for Tumor-Directed Lymphocyte Response | Hackensack University Medical Center | 2026 | $467,261 |
| Mouse model for solid Epstein-Barr Virus-driven cancers | Univ of North Carolina Chapel Hill | 2026 | $394,214 |
Who has won Cancer Control grants before
From fiscal 2021 to 2025, Cancer Control (93.399) awarded $814 million across 113 grant awards, an average of $7.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Ecog-Acrin Medical Research Foundation, Inc. | Pennsylvania | 1 | $87.9 million |
| NRG Oncology Foundation Inc | Pennsylvania | 1 | $54.3 million |
| Alliance NCTN Foundation | Illinois | 1 | $50.2 million |
| Oregon Health & Science University | Oregon | 2 | $34.4 million |
| University of Rochester | New York | 1 | $29.8 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-25-083 still open?
No. It closed on January 7, 2026.
Who can apply for Co-infection and Cancer (R21 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Co-infection and Cancer (R21 Clinical Trial Not Allowed)?
Closed January 7, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-25-083?
NIH RePORTER lists 2 projects funded under PAR-25-083 in fiscal 2026, at 2 institutions. The most were at Hackensack University Medical Center, Univ of North Carolina Chapel Hill.
Who has won Cancer Control grants before?
The largest recipients over five fiscal years were Ecog-Acrin Medical Research Foundation, Inc., NRG Oncology Foundation Inc, Alliance NCTN Foundation. The program made 113 awards worth $814 million in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)